CABP CE Eligible

The Biotherapies Spotlight Session will cover several diverse topics. The use of controlled incremental filtration microfluidics rather than monoclonal antibody selection systems to isolate B-cells from whole blood will be discussed. A comprehensive analysis of the heterogeneity of megakaryocytes produced from umbilical cord CD34+ cells will be presented. The impact of the growth of CAR T-cell therapies over the past 10 years on the field of cellular therapies will be reviewed. Two novel biotherapies will be discussed. Autoantibodies directed to coagulation factor VIII which inhibit its function is problematic for many patients with hemophilia A. One novel biotherapy involves the use of genetically engineered T-cells to eliminate B-cells producing antibodies to coagulation factor VIII. Another novel biotherapy makes use of a small molecule to increase gamma-globin production by red blood cells from patients with sickle cell disease.

Dr. David F. Stroncek MD

National Institutes of Health

Appearances